secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001438533-25-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share
--------------------------------------------------------------------------------

- Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.
- FILSPARI U.S. net sales $55.9M; 703 new patient start forms in quarter.
- Net loss $41.2M ($0.47/share) vs $136.1M ($1.76/share) YoY; adj. net loss $16.9M.
- Cash & securities $322.2M; sNDA submitted for full approval of FILSPARI in FSGS.
- EU and UK converted FILSPARI to full approval in IgAN; $17.5M milestone from CSL Vifor expected Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/0001438533-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/tvtx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer